Skip to content

Study · Animal study (in vivo) · mouse · 2020

6 results

Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand.

Yao M, Watanabe M, Sun S, Tokodai K, Cerami A, Brines M, Östenson CG, Ericzon BG, Lundgren T, Kumagai-Braesch M

Transplantation1 Oct 2020Cited by 6 (Europe PMC)

PMID32345869 (opens in a new tab)DOI10.1097/tp.0000000000003284 (opens in a new tab)PepBankPUB-32345869
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with allogeneic islet transplantation, cibinetide ameliorated the local inflammatory responses in the liver.

    In plain wordsIn mice with transplanted islets, cibinetide reduced the inflammation in the liver around the graft.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseLocal inflammatory response in the liver
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic C57BL/6N mice given BALB/c islets via the portal vein (allogeneic PITx)
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    120 µg/kg · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Cibinetide ameliorated the local inflammatory responses in the liver
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic C57BL/6N (H-2) mice were transplanted with 320 (marginal) or 450 (standard) islets from BALB/c (H-2) mice via the portal vein.
    Summary · context
    Recipients were treated perioperative and thereafter daily during 14 d with cibinetide (120 µg/kg), with or without tacrolimus injection (0.4 mg/kg/d) during days 4-14 after transplantation.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with allogeneic islet transplantation, cibinetide improved glycemic control immediately after transplantation.

    In plain wordsIn mice with transplanted islets, cibinetide improved blood sugar control right after the transplant.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Direction not reportedGlycemic control after allogeneic PITx
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic C57BL/6N mice given BALB/c islets via the portal vein (allogeneic PITx)
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    120 µg/kg · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    improved glycemic control immediately after allogeneic PITx
    2 context sentences
    Summary · context
    Streptozotocin-induced diabetic C57BL/6N (H-2) mice were transplanted with 320 (marginal) or 450 (standard) islets from BALB/c (H-2) mice via the portal vein.
    Summary · context
    Graft function was assessed using nonfasting glucose measurements.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with allogeneic islet transplantation, cibinetide significantly delayed the onset of allograft loss.

    In plain wordsIn mice with transplanted islets, cibinetide delayed the time when the graft was lost.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseTime to allograft loss
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic C57BL/6N mice given BALB/c islets via the portal vein (allogeneic PITx)
    Outcome group
    Islet protection · Endocrine and hormones
    Studied dose
    120 µg/kg · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    significantly delayed the onset of allograft loss.
    1 context sentence
    Summary · context
    Streptozotocin-induced diabetic C57BL/6N (H-2) mice were transplanted with 320 (marginal) or 450 (standard) islets from BALB/c (H-2) mice via the portal vein.
  4. 04LabIn vitro (cells)Efficacy outcome

    In mouse bone-marrow-derived immature dendritic cells in vitro, cibinetide lowered dendritic cell maturation.

    In plain wordsIn mouse cells in the lab, cibinetide lowered the maturing of immune dendritic cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseDendritic cell maturation
    Study

    mousen: not reported in source

    Bone-marrow-derived immature dendritic cells (in vitro)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments indicated that cibinetide lowered bone-marrow-derived-immature-dendritic cell maturation
    1 context sentence
    Summary · context
    Cibinetide's effects on dendritic cell maturation were investigated in vitro.
  5. 05LabIn vitro (cells)Efficacy outcome

    In mouse bone-marrow-derived immature dendritic cells in vitro, cibinetide subsequently reduced the allogeneic T-cell response.

    In plain wordsIn mouse cells in the lab, cibinetide reduced the response of T cells to foreign cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseAllogeneic T-cell response
    Study

    mousen: not reported in source

    Bone-marrow-derived immature dendritic cells (in vitro)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    subsequently reduced allogeneic T-cell response.
    1 context sentence
    Summary · context
    Cibinetide's effects on dendritic cell maturation were investigated in vitro.

Studies that did not test the peptide alone1

In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cibinetide (ARA-290).

  1. 06AnimalNot a test of Cibinetide (ARA-290) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic mice with allogeneic islet transplantation, cibinetide combined with low-dose tacrolimus significantly improved long-term graft survival.

    In plain wordsIn mice with transplanted islets, cibinetide together with low-dose tacrolimus improved how long the graft survived.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseLong-term graft survival with low-dose tacrolimus
    Study

    mousen: not reported in source

    Streptozotocin-induced diabetic C57BL/6N mice given BALB/c islets via the portal vein (allogeneic PITx)
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    Combination treatment with cibinetide and low-dose tacrolimus significantly improved long-term graft survival following allogeneic PITx.
    1 context sentence
    Summary · context
    Recipients were treated perioperative and thereafter daily during 14 d with cibinetide (120 µg/kg), with or without tacrolimus injection (0.4 mg/kg/d) during days 4-14 after transplantation.

    In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.